Skip to main content

Table 1 Clinical characteristics of patients (means ± SEM)

From: Perindopril treatment promote left ventricle remodeling in patients with heart failure screened positive for autoantibodies against angiotensin II type 1 receptor

Index

(+) anti-AT1-AR

(−) anti-AT1-AR

P-value

(n = 82)

(n = 56)

Demographic

   

Age (years)

66.6 ± 1.2

65.1 ± 1.6

ns

Sex (male)

42 (51.2%)

30 (53.6%)

ns

BMI (kg/m2)

24.3 ± 0.9

24.3 ± 0.6

ns

Disease history (years)

6.1 ± 0.3

8.7 ± 0.4

<0.01

Aetiology

   

CAD cases (%)

24 (29.3%)

26 (46.4%)

ns

DCM cases (%)

26 (31.7%)

8 (14.3%)

ns

HHD cases (%)

32 (39.0%)

22 (39.3%)

ns

Physiological characteristics

   

Heart rate (bpm)

94.2 ± 1.2

93.8 ± 1.2

ns

SBP (mmHg)

129.9 ± 1.8

125.0 ± 1.8

ns

DBP (mmHg)

78.2 ± 0.9

75.5 ± 1.1

ns

LVEDD (mm)

69.5 ± 0.6

69.9 ± 0.9

ns

LVESD (mm)

56.2 ± 0.6

55.7 ± 0.8

ns

LVEF (%)

34.1 ± 0.6

33.8 ± 0.9

ns

6 min walk test (m)

303.8 ± 3.7

301.8 ± 4.3

ns

  1. CAD: coronary artery disease; DCM: dilated cardiomyopathy; HHD: hypertensive heart disease; SBP: systolic blood pressure; DBP: diastolic blood pressure; LVEDD: left ventricular end-diastolic dimension; LVESD: left ventricular end-systolic dimension; LVEF: left ventricular ejection fraction.